BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 17360989)

  • 1. A comparison of allografting with autografting for newly diagnosed myeloma.
    Bruno B; Rotta M; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Sorasio R; Omedè P; Baldi I; Bringhen S; Massaia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Storb R; Ciccone G; Boccadoro M
    N Engl J Med; 2007 Mar; 356(11):1110-20. PubMed ID: 17360989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
    Garban F; Attal M; Michallet M; Hulin C; Bourhis JH; Yakoub-Agha I; Lamy T; Marit G; Maloisel F; Berthou C; Dib M; Caillot D; Deprijck B; Ketterer N; Harousseau JL; Sotto JJ; Moreau P
    Blood; 2006 May; 107(9):3474-80. PubMed ID: 16397129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.
    Giaccone L; Storer B; Patriarca F; Rotta M; Sorasio R; Allione B; Carnevale-Schianca F; Festuccia M; Brunello L; Omedè P; Bringhen S; Aglietta M; Levis A; Mordini N; Gallamini A; Fanin R; Massaia M; Palumbo A; Ciccone G; Storb R; Gooley TA; Boccadoro M; Bruno B
    Blood; 2011 Jun; 117(24):6721-7. PubMed ID: 21490341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
    Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.
    Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Busque L; Ahmad I; Roy J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):951-7. PubMed ID: 22155507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
    Badros A; Barlogie B; Siegel E; Cottler-Fox M; Zangari M; Fassas A; Morris C; Anaissie E; Van Rhee F; Tricot G
    J Clin Oncol; 2002 Mar; 20(5):1295-303. PubMed ID: 11870172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
    Kröger N; Schwerdtfeger R; Kiehl M; Sayer HG; Renges H; Zabelina T; Fehse B; Tögel F; Wittkowsky G; Kuse R; Zander AR
    Blood; 2002 Aug; 100(3):755-60. PubMed ID: 12130482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
    Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
    Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
    Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
    Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
    Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.
    Bruno B; Rotta M; Patriarca F; Mattei D; Allione B; Carnevale-Schianca F; Sorasio R; Rambaldi A; Casini M; Parma M; Bavaro P; Onida F; Busca A; Castagna L; Benedetti E; Iori AP; Giaccone L; Palumbo A; Corradini P; Fanin R; Maloney D; Storb R; Baldi I; Ricardi U; Boccadoro M
    Blood; 2009 Apr; 113(14):3375-82. PubMed ID: 19064724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.